65,437 trials
Atopic Dermatitis
Primary: Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 — 83.7; 83.3 Percentage of participants
Cancer of Prostate · Cancer of the Prostate · Neoplasms, Prostate
Primary: Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine — 100; 100 percentage of participants
Tourette Syndrome
Primary: Change From Baseline to Week 8 in the YGTSS TTS — -6.1; -7.4; -8.0 Least Squares Mean (Standard Error) — p=0.4326
Birth Setting · Maternal Health
Primary: Hospital-based Delivery Rate — 76; 53 Participants
Peripheral Solitary Pulmonary Nodule or Tuberculoma
Primary: Comparing the Inflammatory Markers During the Operation After the Intervention of the Each Group — 33; 35; 39; 42 pg/L — p=0.025
GastroEsophageal Cancer
Primary: The Completion Rate of Chemotherapy in Combination With Chemoradiation — 23 Participants
Pressure Ulcer Prevention
Primary: Change in Skin Surface Temperature From Baseline — 3.1; 3.8; 3.0; 3.3 °C
Post-traumatic Stress Disorder
Primary: Change in Clinician-Administered PTSD Scale (CAPS) — 96.0; 90.7; 66.3; 86.2 score on a scale
Partially Edentulous Jaw
Primary: Marginal Bone Level Alteration — -0.09 Millimeter
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Tuberculosis
Primary: Clearance Relative to Bioavailability (CL/F) for Rifapentine (RPT) for Intensive and Sparse PK — 1.4; 1.50 L/hr
Renal Dialysis
Primary: Erythropoietin (EPO) — -6000.0; -1714.3 u/mth
Schizophrenia
Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59
Atrial Fibrillation
Primary: Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis…
Human Immunodeficiency Virus · Acquired Immunodeficiency Syndrome · Opiate Addiction
Primary: CD4 Count Absolute — 486.15; 403.92 cells/uL